Caribou Biosciences (NASDAQ:CRBU) Stock Price Up 0.6% – Here’s Why

Caribou Biosciences, Inc. (NASDAQ:CRBU) shares traded up 0.6% during trading on Tuesday . The company traded as high as $1.64 and last traded at $1.59. 1,035,077 shares changed hands during mid-day trading, an increase of 13% from the average session volume of 918,003 shares. The stock had previously closed at $1.58.

Analyst Upgrades and Downgrades

CRBU has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, October 8th. Citigroup increased their target price on Caribou Biosciences from $5.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, November 3rd. HC Wainwright lifted their price target on Caribou Biosciences from $3.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Finally, Truist Financial set a $7.00 price target on shares of Caribou Biosciences in a research note on Tuesday, November 4th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Caribou Biosciences presently has an average rating of “Hold” and an average target price of $8.00.

Caribou Biosciences Stock Performance

The firm has a 50-day moving average of $1.81 and a 200-day moving average of $1.96. The firm has a market capitalization of $148.62 million, a P/E ratio of -0.94 and a beta of 2.61.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. Caribou Biosciences had a negative return on equity of 69.85% and a negative net margin of 1,690.45%.The firm had revenue of $2.20 million during the quarter, compared to analysts’ expectations of $1.94 million. On average, research analysts forecast that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Institutional Trading of Caribou Biosciences

A number of institutional investors have recently made changes to their positions in CRBU. AQR Capital Management LLC raised its holdings in shares of Caribou Biosciences by 741.6% during the first quarter. AQR Capital Management LLC now owns 525,878 shares of the company’s stock valued at $480,000 after purchasing an additional 463,391 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Caribou Biosciences in the first quarter worth approximately $61,000. Aberdeen Group plc grew its position in Caribou Biosciences by 118.3% in the 2nd quarter. Aberdeen Group plc now owns 897,579 shares of the company’s stock worth $1,131,000 after purchasing an additional 486,435 shares during the period. Vanguard Personalized Indexing Management LLC raised its stake in Caribou Biosciences by 69.5% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 40,813 shares of the company’s stock valued at $51,000 after buying an additional 16,736 shares during the last quarter. Finally, CWM LLC raised its stake in Caribou Biosciences by 53.5% during the 2nd quarter. CWM LLC now owns 33,839 shares of the company’s stock valued at $43,000 after buying an additional 11,798 shares during the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.